ID: MRFR/HC/6760-HCR | February 2023 | Region: Global | 111 Pages
Musculoskeletal System Disorders Market is expected to cross USD 5,323.53 Million at a CAGR of 6.80% during forecast period
$5,323.53 Million
6.80%
North America
2022-2030
The musculoskeletal system disorders market is expected to reach USD 5,323.53 Million by 2030 at 6.80% CAGR during the forecast period 2022-2030.
Musculoskeletal System Disorders Market Synopsis
The number of musculoskeletal system disorder cases is increasing globally, fueling musculoskeletal system disorder market growth. Musculoskeletal system disorders are the second-highest contributor to global disability and an estimated 20%–33% of people across the globe live with a painful musculoskeletal condition.
Musculoskeletal disorders are most common in low- and middle-income countries and these disorders require lifelong care to manage.
Musculoskeletal System Disorders Market Influencer
Rising prevalence of musculoskeletal disorders and increasing reimbursement offered to patients by health insurance providers.
Musculoskeletal System Disorders Market Drivers
Musculoskeletal System Disorders Market Restraints
Musculoskeletal System Disorders Market Segmentation
By Type
By Treatment
By End User
By Region
Musculoskeletal System Disorders Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size | USD 5,323.53 Million |
CAGR | 6.80% |
Base Year | 2021 |
Forecast Period | 2022-2030 |
Historical Data | 2020 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Type, Treatment, End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | AB Science (France), AbGenomics International, Inc. (US), Alder BioPharmaceuticals,Inc. (US), Amgen Inc. (US), Lexicon Pharmaceuticals, Inc. (US), LG Chem (South Korea), OrthoTrophix, Inc. (US), Tarsa Therapeutics, Inc. (US), PhytoHealth Corporation (Taiwan), Eisai Co., Ltd (Japan), Astellas Pharma Inc. (Japan), AstraZeneca (UK), Baxter (US), GlaxoSmithKline PLC (UK) |
Key Market Opportunities | New product launches and R&D Amongst major key Players |
Key Market Drivers |
|
The musculoskeletal system disorders market is projected to grow at a 6.80% CAGR between 2022-2030.
The Americas are predicted to have the largest share in the musculoskeletal system disorders market.
The musculoskeletal system disorders market is predicted to touch USD 5,323.53 Million by 2030.
Key competitors in the musculoskeletal system disorders market include GlaxoSmithKline PLC (UK), Baxter (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Eisai Co., Ltd (Japan), PhytoHealth Corporation (Taiwan), Tarsa Therapeutics, Inc. (US), OrthoTrophix, Inc. (US), LG Chem (South Korea), Lexicon Pharmaceuticals, Inc. (US), Amgen Inc. (US), Alder BioPharmaceuticals,Inc. (US), AbGenomics International, Inc. (US), and AB Science (France).
High surgery cost may restrict market growth.